Nichi-iko Pharmaceutical Co. Ltd. | Ownership
Companies that own Nichi-iko Pharmaceutical Co. Ltd.
The Vanguard Group, Inc.
1,097,955
1.81%
39,300
0%
07/31/2018
Nomura Asset Management Co., Ltd.
897,897
1.48%
13,898
0.01%
07/31/2018
Dimensional Fund Advisors LP
675,150
1.11%
86,900
0%
04/30/2018
BlackRock Fund Advisors
524,650
0.87%
2,600
0%
09/06/2018
Daiwa Asset Management Co. Ltd.
496,000
0.82%
53,101
0.01%
07/31/2018
Nikko Asset Management Co., Ltd.
390,500
0.64%
0
0%
08/20/2018
Norges Bank Investment Management
377,699
0.62%
-182,114
0%
12/31/2017
AXA Investment Managers UK Ltd.
326,600
0.54%
-43,125
0.02%
07/31/2018
TIAA-CREF Investment Management LLC
191,250
0.32%
47,900
0%
03/31/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
189,059
0.31%
-16,340
0.01%
07/31/2018
| Address |
1-6-21 Sogawa
Toyama Toyama 930
Japan
|
|
Employees
|
- |
| Website |
http://www.nichiiko.co.jp |
| Updated |
07/08/2019 |
| Nichi-Iko Pharmaceutical Co., Ltd. develops, manufactures, and markets generic pharmaceutical products. Its products are classified into Prescriptive and General Over-the-Counter (OTC) drugs. These products are used for the treatment of circulatory, digestive, respiratory, central and peripheral nervous systems problems. |
